Search
Search Results
##search.searchResults.foundPlural##
-
IMMUNOTHERAPY FOR EPSTEIN-BARR VIRUS-RELATED LYMPHOMAS
1293PDF: 639HTML: 6934 -
GROWTH AND ENDOCRINE FUNCTION IN TUNISIAN THALASSEMIA MAJOR PATIENTS
5816PDF: 1089HTML: 484TABLE: 228FIGURES: 304 -
Tacrolimus Associated Posterior Reversible Encephalopathy Syndrome – A Case Series and Review
3710PDF: 1615HTML: 4510CoverLetter: 223Figure1: 238 -
Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio
2313PDF: 1689HTML: 651 -
Status Epilepticus Due to Severe HHV-6 Encephalitis in an Allogeneic Stem Cell Transplant Recipient
1251PDF: 881HTML: 2197Figue 1: 205 -
-
DIAGNOSTIC VALUE OF BRONCHOALVEOLAR LAVAGE IN LEUKEMIC AND BONE MARROW TRANSPLANT PATIENTS: THE IMPACT OF ANTIMICROBIAL THERAPY
2047PDF: 869HTML: 2224Table 1: 224Table 2: 241Table 3: 237Table 4: 231Table 5: 231Tble 6: 227Cover Letter: 242Greene Tab.7: 248 -
LYMPHOPROLIFERATIVE SYNDROMES ASSOCIATED WITH HUMAN HERPESVIRUS-6A AND HUMAN HERPESVIRUS-6B
3893PDF: 1672HTML: 873Figures . Eliassian: 273 -
PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations
3752PDF: 2620HTML: 1661 -
Focusing On A Unique Innate Memory Cell Population Of Natural Killer Cells In The Fight Against COVID-19: Harnessing The Ubiquity Of Cytomegalovirus Exposure Memory Cell Population Of Natural Killer Cells in COVID-19 and Cytomegalovirus Exposure
1322PDF: 991HTML: 351 -
Bordetella Bronchiseptica in the Immunosuppressed Population – A Case Series and Review.
2623PDF: 1386HTML: 1841CoverLetter: 220 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
1983PDF: 1227HTML: 343 -
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
3497PDF: 1564HTML: 4085 -
HEMATOLOGY PATIENT PROTECTION DURING THE COVID-19 PANDEMIC IN ITALY: A NATIONWIDE NURSING SURVEY Hematology patient protection during the COVID-19
1788PDF: 658HTML: 300 -
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment
2278PDF: 1643HTML: 688 -
-
-
IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
5083PDF: 2964HTML: 2357 -
ZYGOMYCOSIS IN IMMUNOCOMPROMISED NON-HAEMATOLOGICAL PATIENTS
3012PDF: 1024HTML: 7504 -
MODERN IMMUNOTHERAPY OF ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS
2420PDF: 1383HTML: 17214Bassan Fig.1: 175Bassan Fig.2: 282Bassan Fig.4: 168Fig.3: 250 -
-
MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS.
5162PDF: 1366HTML: 1939Untitled: 227Untitled: 211 -
Allogeneic transplantation in patients with advanced systemic mastocytosis: case report of a single center experience Allogeneic Transplantation in Systemic Mastocytosis
2140PDF: 159HTML: 43 -







